Markets:

Overview

News

Currencies

International

Treasuries

uniQure N.V. - Ordinary Shares (NQ:QURE)

20.71 -0.57 (-2.68%)

Delayed Quote Updated: 1:54 PM EDT, Oct 14, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about uniQure N.V. - Ordinary Shares

< Previous 1 2

...

11 12 13 14 15 16 17 18 Next >

Stocks That Hit 52-Week Lows On Tuesday ↗

July 25, 2023

On Tuesday, 56 companies set new 52-week lows.

Via Benzinga

Stocks That Hit 52-Week Lows On Friday ↗

July 21, 2023

On Friday, 54 companies hit new 52-week lows.

Via Benzinga

Why uniQure Stock Cratered This Week ↗

June 22, 2023

An interim analysis for the company's Huntington's disease gene therapy wasn't a hit with investors.

Via The Motley Fool

Chardan Capital Maintains Buy Rating for uniQure: Here's What You Need To Know ↗

June 22, 2023

Via Benzinga

Stocks That Hit 52-Week Lows On Monday ↗

July 24, 2023

On Monday morning, 70 companies achieved new lows for the year.

Via Benzinga

Stocks That Hit 52-Week Lows On Thursday ↗

July 20, 2023

During Thursday's session, 40 stocks hit new 52-week lows.

Via Benzinga

Why UniQure Stock Is Trading Down Today ↗

June 21, 2023

UniQure N.V. (NASDAQ: QURE) shares are lower after the company announced interim data from the Phase I/II trial of AMT-130 in Huntington's Disease.

Via Benzinga

Where uniQure Stands With Analysts ↗

June 21, 2023

Via Benzinga

uniQure Announces Leadership Addition to Support Advancement of Clinical Programs

June 26, 2023

~ Walid Abi-Saab, M.D., appointed Chief Medical Officer, will bring extensive track record in leading drug development and execution ~

From uniQure Inc.

Via GlobeNewswire

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against uniQure N.V. and Encourages Investors with Losses to Contact the Firm

June 22, 2023

From The Schall Law Firm

Via Business Wire

Nordson To Rally Over 14%? Here Are 10 Other Analyst Forecasts For Thursday ↗

June 22, 2023

Chardan Capital cut the price target for uniQure N.V. (NASDAQ: QURE) from $45 to $27. Chardan Capital analyst Matthew Barcus maintained a Buy rating. uniQure shares fell 1.5% to $11.45 in pre-market...

Via Benzinga

Why uniQure Stock Is Crashing Today ↗

June 21, 2023

Investors are focusing on the negative parts of the biotech company's interim results.

Via The Motley Fool

6 Analysts Have This to Say About uniQure ↗

May 11, 2023

Via Benzinga

Crude Oil Rises 2%; LumiraDx Shares Spike Higher ↗

June 21, 2023

U.S. stocks traded lower toward the end of trading, with Nasdaq Composite dropping over 100 points on Wednesday. The Dow traded down 0.04% to 34,040.13 while the NASDAQ fell 0.77% to 13,562.00. The S&P...

Via Benzinga

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against uniQure N.V. and Encourages Investors with Losses to Contact the Firm

June 21, 2023

From The Schall Law Firm

Via Business Wire

Why ToughBuilt Industries Shares Are Trading Lower By Over 46%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

June 21, 2023

Gainers Advanced Health Intelligence Ltd. (NASDAQ: AHI) shares jumped 209.5% to $2.29 after the company signed a Letter of Intention with UAE-Based e-script medicine management company Pharmak...

Via Benzinga

Nasdaq Tumbles 1%; Patterson Companies Earnings Beat Views ↗

June 21, 2023

U.S. stocks traded mostly lower midway through trading, with Nasdaq Composite dropping over 100 points on Wednesday.

Via Benzinga

Uniqure Crashes To Six-Year Low On Muddy Results For Huntington's Gene Therapy ↗

June 21, 2023

The company is working on a one-time treatment for Huntington's disease.

Via Investor's Business Daily

Dow Drops Over 100 Points; Winnebago Industries Posts Downbeat Sales ↗

June 21, 2023

U.S. stocks traded lower this morning, with Dow Jones dropping over 100 points on Wednesday. Following the market opening Wednesday, the Dow traded down 0.41% to 33,914.60 while the NASDAQ fell 0.31%...

Via Benzinga

uniQure Announces Update on U.S. Phase I/II Clinical Trial of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease

June 21, 2023

From uniQure Inc.

Via GlobeNewswire

uniQure announces achievement of $100 million milestone related to hemophilia B gene therapy

June 20, 2023

Milestone payment triggered by first commercial sale of HEMGENIX® in U.S. by CSL Behring

From uniQure Inc.

Via GlobeNewswire

uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 16, 2023

From uniQure Inc.

Via GlobeNewswire

uniQure's Hemgenix Royalty Sales Agreement Extends Cash Runway, Relieves Near-Term Commercial Risk, Says Analyst ↗

May 15, 2023

uniQure N.V. (NASDAQ: QURE) agreed to sell a portion of the royalty rights due from CSL Behring from Hemgenix (etranacogene dezaparvovec-drbl) net sales to HealthCare Royalty and Sagard Healthcare

Via Benzinga

uniQure Announces Sale of Royalty Interest in HEMGENIX® for Up To $400 Million

May 15, 2023

From uniQure Inc.

Via GlobeNewswire

Recap: uniQure Q1 Earnings ↗

May 09, 2023

uniQure (NASDAQ:QURE) reported its Q1 earnings results on Tuesday, May 9, 2023 at 07:05 AM. Here's what investors need to know about the announcement. Earnings uniQure missed estimated earnings by...

Via Benzinga

uniQure Announces First Quarter 2023 Financial Results and Highlights Recent Company Progress

May 09, 2023

From uniQure Inc.

Via GlobeNewswire

uniQure Announces Major Presence at Upcoming American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

May 02, 2023

From uniQure Inc.

Via GlobeNewswire

uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 02, 2023

From uniQure Inc.

Via GlobeNewswire

uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 13, 2023

From uniQure Inc.

Via GlobeNewswire

Hefty Listing Price Of New Drugs For Cancer, Rare Diseases Put Pressure On Annual Hike For Older Drugs ↗

March 10, 2023

New branded medicines are coming to market with ever-higher price tags as soon as the first day. Amgen Inc's (NASDAQ: AMGN) lung cancer treatment, Lumakras, carried a hefty price tag of $17,900 per...

Via Benzinga

< Previous 1 2

...

11 12 13 14 15 16 17 18 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

uniQure N.V. - Ordinary Shares (NQ:QURE)

All News about uniQure N.V. - Ordinary Shares

Starting at /week.